Keywords: آنتی بادی ضد دارو; ADA; anti-drug antibody; nADA; neutralizing anti-drug antibody; PASI; Psoriasis Area and Severity Index; PK; pharmacokinetics; Q2W; every 2 weeks; Q4W; every 4 weeks; TE-ADA; treatment-emergent anti-drug antibody;
مقالات ISI آنتی بادی ضد دارو (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: آنتی بادی ضد دارو; A1PI; Virus; Prions; Safety; Purity; Stability; ADA; anti-drug antibody; A1PI; alpha1-proteinase inhibitor; B19V; parvovirus B19; BVDV; bovine viral diarrhea virus; CJD; Creutzfeldt-Jakob-Disease; CPV; canine parvovirus; DTT; dithiothreitol; EMA; European
Keywords: آنتی بادی ضد دارو; Biologic; Ocular; Ophthalmic; Rabbit; Anti-drug antibody; Inflammation; 3Rs;
Keywords: آنتی بادی ضد دارو; ADA; anti-drug antibody; ADCC; antibody-dependent cell cytotoxicity; ADCP; antibody-dependent cell phagocytosis; BiTE; bi-specific T cell engagers; CDC; complement-dependent cytotoxicity; CRA; cytokine release assays; CRS; cytokine release syndrome; DC; d
Keywords: آنتی بادی ضد دارو; ADA; anti-drug antibody; ALN; alendronate; AUC; area under curve; BFR/BS; bone formation rate per bone surface; BMD; bone mineral density; bSEM; backscattered scanning electron microscopy; CKD-MBD; chronic kidney disease-mineral and bone disorder; CTX; ca
Keywords: آنتی بادی ضد دارو; ADA; anti-drug antibody; AE; adverse event; CCL18; chemokine (C-C motif) ligand 18; ECL; electrochemiluminescence; ELISA; enzyme-linked immunosorbent assay; ERT; enzyme replacement therapy; GD; Gaucher disease; RIP; radioimmunoprecipitation; TEAE; treatme
Keywords: آنتی بادی ضد دارو; MSD; MesoScale Discovery; ECL; electrochemiluminescence; ACE; affinity capture elution; ADA; anti-drug antibody; TAb; therapeutic antibody; MRD; minimum require dilution; TMB; 3,3â²,5,5â² tetramethylbenzidine; HRP; horseradish peroxidase; NHS; normal hu
Keywords: آنتی بادی ضد دارو; Anti-drug antibody; Confirmatory; Cut point; Immunoassay; Immunogenicity; Screening; Specificity;
Keywords: آنتی بادی ضد دارو; asthma; eosinophil; phase 3; reslizumab; ACQ; Asthma Control Questionnaire; ADA; anti-drug antibody; AE; adverse event; FAS; full analysis set; ICS; inhaled corticosteroid; LABA; long-acting β-agonist; LS; least squares; SABA; short-acting β-agonist;
Keywords: آنتی بادی ضد دارو; Biosimilar; Extrapolation; Inflammatory Bowel Disease; CT-P13; Infliximab; Infliximab-dyyb; ADA; anti-drug antibody; ADCC; antibody-dependent cell cytotoxicity; AS; ankylosing spondylitis; CD; Crohn's disease; CRP; C-reactive protein; EMA; European Medi
Keywords: آنتی بادی ضد دارو; ADA; anti-drug antibody; ACP; assay cutpoint; CDM; compact disc microstructures; CDR; complementary determining region; Fc; Fragment crystallizable; F/T; ratio of free to total drug concentrations; iNAb; indirect NAb assessment; LLRD; lower limit of relia
Keywords: آنتی بادی ضد دارو; Immunogenicity; Anti-drug antibody; ADA; Drug interference; Drug tolerance; Target interference; Immunoassay; Ligand binding assays;
Keywords: آنتی بادی ضد دارو; TPP; therapeutic protein product; ADA; anti-drug antibody; mAb; monoclonal antibody; RA; rheumatoid arthritis; MS; multiple sclerosis; IBD; inflammatory bowel disease; NAb; neutralizing ADA; non-NAb; non-neutralizing ADA; PK; pharmacokinetics; PRCA; pure
Keywords: آنتی بادی ضد دارو; Anti-drug antibody; Immunoassays; Immunogenicity; Screening cut point; Software
Keywords: آنتی بادی ضد دارو; Anti-drug antibody; Confirmatory; Cut point; Immunoassay; Specificity;
Keywords: آنتی بادی ضد دارو; Multi-domain biotherapeutic; Immunogenicity response characterization; Anti-drug antibody
Keywords: آنتی بادی ضد دارو; ADA; anti-drug antibody; ABT; antigen binding test; GSH; reduced glutathione; Natalizumab; Certolizumab; Anti-drug antibody (ADA); Bispecific antibody; Drug interference;
Keywords: آنتی بادی ضد دارو; Peptide; Liquid-chromatography-tandem mass spectrometry; Anti-drug antibody; Free vs. total; Ultrafiltration; Protein A/G;
Keywords: آنتی بادی ضد دارو; 3Rs; replacement, refinement and reduction of animals in research; ACSA; Agricultural Chemicals Safety Assessment; ADA; anti-drug antibody; CNS; central nervous system; DBS; dried blood spot; DART; developmental and reproductive toxicity; DRF; dose range
Development of an anti-EPO antibody detection kit based on lab-on-a-chip and bridging antibody technologies
Keywords: آنتی بادی ضد دارو; EPO; Erythropoietin; ADA; Anti-drug antibody; PRCA; Pure red cell aplasia; ELISA; Enzyme-linked immunosorbent assay; SPR; Surface plasmon resonance; Ab; antibody; FL; fluorescence; T/R ratio; Test/reference ratio; POC; Point of care;
Transitioning from first- to second-generation biosimilars: An appraisal of regulatory and post-marketing challenges
Keywords: آنتی بادی ضد دارو; ACR; American College of Rheumatology; ADAb; anti-drug antibody; ADCC; antibody-dependent cell-mediated cytotoxicity; AIFA; Italian Medicines Agency; CDC; complement-dependent cytotoxicity; CHMP; Committee for Medicinal Products for Human Use; DAS28; 28-j
Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study
Keywords: آنتی بادی ضد دارو; Cerliponase alfa; Enzyme replacement therapy; CLN2; Neuronal ceroid lipofuscinosis; Anti-drug antibodies; Hypersensitivity; Immunogenicity; ADA; anti-drug antibody; ICV; intracerebroventricular.; ML; motor-language.; NAb; neutralizing anti-drug antibody.;
Comparison of different immunoassay methods to detect human anti-drug antibody using the WHO erythropoietin antibody reference panel for analytes
Keywords: آنتی بادی ضد دارو; ADA; anti-drug antibody; SPR; surface plasmon resonance; ECL; electrochemiluminescence; BLI; biolayer interferometry; EPO; erythropoietin; WHO; World Health Organization; NIBSC; National Institute for Biological Standards and Control; N-factor; normalizat
Theranostic of biopharmaceuticals
Keywords: آنتی بادی ضد دارو; α3Gal; galactose-α1,3-galactose; ADA; anti-drug antibody; aHUS; atypical hemolytic uremic syndrome; ARIC; ADA-related immune complex; CEP17; centromere of chromosome 17; CCP; cyclic citrullinated peptide; CTLA-4; cytotoxic T-lymphocyte-associated protei
Research paperClinical immunogenicity of the d-amino acid peptide therapeutic etelcalcetide: Method development challenges and anti-drug antibody clinical impact assessments
Keywords: آنتی بادی ضد دارو; Immunogenicity; Calcimimetic; Etelcalcetide; Surface plasmon resonance; Anti-drug antibody; ADA impact assessment;
Higher body mass index and anti-drug antibodies predict the discontinuation of anti-TNF agents in Korean patients with axial spondyloarthritis
Keywords: آنتی بادی ضد دارو; Adalimumab; Anti-drug antibody; Axial spondyloarthritis; Infliximab; Tumor necrosis inhibitors; Adalimumabe; Anticorpos antifármacos; Espondiloartrite axial; Infliximabe; Inibidores da necrose tumoral;
American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases
Keywords: آنتی بادی ضد دارو; ADAb; anti-drug antibody; AGA; American Gastroenterological Association; AZA; azathioprine; CBC; complete blood count; CD; Crohn's disease; CI; confidence interval; CRP; C-reactive protein; ECLIA; electrochemiluminescence immunoassay; ELISA; enzyme-link
Development, validation, and application of ELISA for detection of anti-HD105 antibodies in pre-clinical safety evaluation using monkeys
Keywords: آنتی بادی ضد دارو; Immunogenicity; Anti-drug antibody; Therapeutic proteins; Preclinical study; Validation; Bispecific antibody;
Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies
Keywords: آنتی بادی ضد دارو; % Predicted FVC; percent of predicted normal forced vital capacity; 6MWT; six-minute walk test; ADA; anti-drug antibody; AE; adverse events; AUC/time; area under the curve over time (reflects a weighted average of exposure over a period from baseline thro
Fate of Multimeric Oligomers, Submicron, and Micron Size Aggregates of Monoclonal Antibodies Upon Subcutaneous Injection in Mice
Keywords: آنتی بادی ضد دارو; IgG antibody; imaging methods; monoclonal antibody; protein aggregation; proteins; ADA; anti-drug antibody; AUC; area under the curve; GPC; gel permeation chromatography; HP-SEC; high performance size-exclusion chromatography; IgG; immunoglobulin G; IV; i
A signaling-enhanced chimeric receptor to activate the ICOS pathway in T cells
Keywords: آنتی بادی ضد دارو; ADA; anti-drug antibody; CD3; cluster of differentiation 3; B7RP1; B7 related protein 1; ICOS; inducible costimulator; TCR; T cell receptor; ICOS-CD3; chimeric receptor consisting of full-length ICOS and the cytoplasmic region of CD3 zeta; ITAM; immune
BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease
Keywords: آنتی بادی ضد دارو; ADA; Anti-drug antibody; BAFF; B-cell activating factor; ERT; Enzyme replacement therapy; FO; Follicular B-cell; GAA; Acid α-glucosidase; MZ; Marginal zone B-cell; rhGAA; Recombinant human GAA; TR; Transitional B-cell; Acid alpha-glucosidase; BAFF; BLyS;
Detection of drug specific circulating immune complexes from in vivo cynomolgus monkey serum samples
Keywords: آنتی بادی ضد دارو; ADA; anti-drug antibody; ALT; alanine aminotransferase; AST; aspartate aminotransferase; BSA; bovine serum albumin; BUN; blood urea nitrogen; CP; cut point; CREA; creatinine; FcγR; Fc-gamma receptor; HQC; high quality control sample; HPLC; high pressure
Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: AÂ randomized trial
Keywords: آنتی بادی ضد دارو; IL-13; IL13Rα1; IL13Rα2; efficacy; safety; pharmacokinetics; pharmacodynamics; ACQ; Asthma Control Questionnaire; ADA; Anti-drug antibody; AE; Adverse event; ECLIA; Electrochemiluminescence immunoassay; Feno; Fraction of exhaled nitric oxide; FPE; Fluti
Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay
Keywords: آنتی بادی ضد دارو; ATA; antibodies-to-adalimumab; CD; Crohn's disease; HMSA; homogenous mobility shift assay; IBD; inflammatory bowel disease; PS; psoriasis; RA; rheumatoid arthritis; TNF-α; tumor necrosis factor-alpha; UC; ulcerative colitis; Adalimumab; Anti-drug antibod
Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII
Keywords: آنتی بادی ضد دارو; ADA; anti-drug antibody; aPCC; activated prothrombin complex concentrate; aPTT; activated partial thromboplastin time; AUC; area under the curve; AUC0-24h; AUC from 0 to 24Â hours; AUC0-last; AUC from 0 to last timepoint; BDD; B-domain deleted; CFT; clo
Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement
Keywords: آنتی بادی ضد دارو; Interferon beta;; Relapsing-remitting multiple sclerosis;; Immunogenicity;; Anti-drug antibody;; Neutralising antibody;; Complement;
Biomarkers for non-human primate Type-I hypersensitivity: Antigen-specific immunoglobulin E assays
Keywords: آنتی بادی ضد دارو; IgE; Anti-drug antibody; Immunogenicity; Hypersensitivity; Non-human primate;
False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay
Keywords: آنتی بادی ضد دارو; CLL; chronic lymphocytic leukemia; CMFs; cell membrane fragments; ADA; anti-drug antibody; ECL; electrochemiluminescent; RTX; rituximab; Ofa; Ofatumumab; MVs; microvesicles; MSD; Meso-Scale Discovery; NC; negative control; PC; positive control; Immunogeni
Adapting dried blood spot sampling for an anti-therapeutic antibody immunogenicity assay
Keywords: آنتی بادی ضد دارو; Dried blood spot; Anti-drug antibody; Immunogenicity; Design of experiment
Correlation of screening and confirmatory results in tiered immunogenicity testing by solution-phase bridging assays
Keywords: آنتی بادی ضد دارو; Anti-drug antibody; Confirmatory assay; Cut point; False positive rate; Screening assay
Antibodies to constant domains of therapeutic monoclonal antibodies: Anti-hinge antibodies in immunogenicity testing
Keywords: آنتی بادی ضد دارو; IVIG; Intravenous immunoglobulin; ADA; anti-drug antibody; RIA; radioimmunoassay; RA; rheumatoid arthritis; Infliximab; Adalimumab; Epitope; Immunogenicity; Anti-drug antibody (ADA);
A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays
Keywords: آنتی بادی ضد دارو; Anti-drug antibody; Cut point; ELISA; Immunoassay; Immunogenicity
A multiple-dose toxicity study of tanezumab in cynomolgus monkeys
Keywords: آنتی بادی ضد دارو; Anti-drug antibody; Cynomolgus monkey; Nerve growth factor; Pharmacokinetics; Tanezumab; Toxicity;
Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet® biolayer interferometry
Keywords: آنتی بادی ضد دارو; Immunogenicity; Anti-drug antibody; Drug tolerance; Biolayer interferometry; Octet; Biosensor
Statistical considerations for calculation of immunogenicity screening assay cut points
Keywords: آنتی بادی ضد دارو; Immunogenicity; Anti-drug antibody; Cut point; False positive rate; Prediction limit;
Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease
Keywords: آنتی بادی ضد دارو; ADA; anti-drug antibody; BSA; bovine serum albumin; CPM; counts per minute; DPBS; Dulbecco's Phosphate Buffered Saline solution; ECL; electrochemiluminescence; EMA; European Medicines Agency; FDA; Food and Drug Administration; HBS-EP; HEPES-buffered salin
Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies
Keywords: آنتی بادی ضد دارو; Anti-drug antibody; Immune complex; Drug interference; Cynomolgus monkey; Immunogenicity
T cell epitope: Friend or Foe? Immunogenicity of biologics in context
Keywords: آنتی بادی ضد دارو; Antigen; MHC; Antibodies; Anti-drug antibody; Antigen presentation; Immunoinformatics; T lymphocyte antigens; T effector cells; T regulatory cells; Tolerance
Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products
Keywords: آنتی بادی ضد دارو; Method validation; Immunogenicity; Immunoassay; Anti-drug antibody